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Abstract
Background: Primary prevention of breast cancer through prophylactic mastectomy can reduce
the risk of malignancy in high-risk individuals. No type of mastectomy completely removes all breast
tissue, but a subcutaneous mastectomy leaves more tissue in situ than does a simple mastectomy.
Case presentation: We report a case of invasive breast cancer in a BRCA2-positive woman 33
years after bilateral subcutaneous mastectomy. To our knowledge, only one case of primary breast
cancer after prophylactic mastectomy in a BRCA1-positive patient has been reported in the
literature and none in BRCA2-positive individuals.
Conclusion: Careful documentation and long follow-up is essential to fully assess the benefits and
risks of preventive surgical procedures in BRCA1 and BRCA2 mutation carriers.
Background
The risk of breast cancer in women who inherit a germline
mutation in the BRCA1 gene can be as high as 20% by the
age of 40 and 50% by the age of 50 [1] and as high as 13%
by the age of 40 and 60% by the age of 50 in BRCA2 muta-
tion carriers [2]. These estimates apply to individuals who
belong to very high risk, multiple-case breast cancer fami-
lies. Prophylactic surgery to reduce cancer risk remains an
option for carriers of BRCA gene mutations; however, its
efficacy is likely to depend on the ability to remove nearly
all breast tissue. Different surgical procedures, (subcuta-
neous or a simple mastectomy), limited patient follow-up
and lack of adequate control population confound the
numerous studies on this subject. Only three reports have
specifically addressed the extent of risk reduction by pro-
phylactic breast removal in BRCA1 and BRCA2-positive
individuals [3-5]. Most surgeons believe that subcutane-
ous mastectomy (SCM) is not optimal for prophylaxis
because a substantial amount of breast tissue remains in
the nipple-areola complex and on the skin flaps, and
therefore it has fallen into disuse. Here, we report a case of
breast cancer occurring following a SCM. A literature
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review using PubMed, searching from 1994 to the present,
revealed this to be the first reported case of breast cancer
occurring post-SCM in a carrier of a BRCA2 gene muta-
tion. We discuss the possible implications of this seem-
ingly uncommon finding.
Case Presentation
A 49 year old G3P2A1 presented in 2002 with a six month
history of a painless lump in her inner left breast. She had
undergone bilateral SCM with immediate implantation of
silicone prostheses at the age of 16 due to extensive fibro-
cystic breast disease with adenosis. On physical examina-
tion a firm, mobile, 1.5 cm nodule was palpated
superficially. There was no associated skin retraction or
thickening. No enlarged abnormal nodes were palpable.
We performed mammographic and sonographic exami-
nations. Mammography, of limited value because of the
previous SCM, did not show any obvious abnormality.
Sonographic examination revealed a 1.5 cm in size, hyp-
oechoic, solid, non-calcified, circumscribed mass, grossly
ovoid with a thin echoic rim, located in the subcutaneous
fat at 9 o'clock in the left breast (Figure 1). Minimal vas-
cular pole was identified on conventional color sonogra-
phy. The imaging findings appeared to indicate a benign
nature of the lesion; however, based on the family history,
patient age, and the recent occurrence of the nodule, exci-
sional biopsy was performed. An infiltrating ductal carci-
noma, apocrine type, grade 2 of 3 of modified Bloom and
Richardson, with associated ductal carcinoma in situ, cri-
briform type, nuclear grade 2 of 3, occupying 10% of
tumor mass (Figures 2A and 2B) was identified. Estrogen
receptor status was strongly positive on most malignant
cells, progesterone receptor moderately positive on 50%
of malignant cells and HER-2/neu was negative (score 0)
with no membrane staining of malignant cells. There was
no evidence of malignancy in 23 lymph nodes examined
following the left axillary contents dissection.
Subsequently, the proband was referred for genetic coun-
seling and found to carry BRCA2: 6503delTT, a mutation
previously described in the French Canadian population
[6]. Family history (Figure 3) was significant for breast
Sonographic examination: 15 mm hypoechoic solid, non-calcified circumscribed mass, with a thin echoic rim, benign in appear- ance, located in subcutaneous fat at 9 o'clock in the left breast Figure 1
Sonographic examination: 15 mm hypoechoic solid, non-calcified circumscribed mass, with a thin echoic rim, benign in appear-
ance, located in subcutaneous fat at 9 o'clock in the left breast.World Journal of Surgical Oncology 2005, 3:52 http://www.wjso.com/content/3/1/52
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photomicrograph 2A) Invasive ductal carcinoma, apocrine type: tumor exhibits an irregular invasive border and forms glandular  structures Figure 2
photomicrograph 2A) Invasive ductal carcinoma, apocrine type: tumor exhibits an irregular invasive border and forms glandular 
structures. Hematoxylin and eosin stain, original magnification × 40. 2B) Invasive ductal carcinoma, apocrine type: cytological 
characteristics of intermediate nuclear grade, prominent nucleoli, and eosinophilic granular cytoplasm. Hematoxylin and eosin 
stain, original magnification × 100.
Pedigree of the family with germline BRCA2: 6503delTT mutation Figure 3
Pedigree of the family with germline BRCA2: 6503delTT mutation. All individuals affected with cancer (ca) are depicted by filled-
in symbols. Individual ID numbers, age at the time of diagnosis (dx) and/or death are below each symbol.World Journal of Surgical Oncology 2005, 3:52 http://www.wjso.com/content/3/1/52
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cancer in proband's father (II-6) who was diagnosed at the
age of 77 and mother (II-7) diagnosed at 79. A 52 years
old paternal cousin (III-3), also affected with breast can-
cer, was previously identified as a BRCA2 mutation carrier
at another institution. Of note, individual III-3's mother
(II-5) and sister (III-2) both had breast cancer and died at
47 and 49 years of age, respectively. There were only two
paternal aunts known to have been affected with breast
cancer at the time of patient's bilateral SCM.
Given the diagnosis of invasive breast cancer and BRCA2
mutation carrier status, our proband opted for prophylac-
tic bilateral salpingo-oophorectomy with hysterectomy,
as well as removal of the nipple-areola complex along
with remaining breast tissue. The pathology examination
identified the presence of bilateral adnexal stromal hyper-
plasia, several leiomyomata in the myometrium as well as
simple ductal epithelial hyperplasia without atypia in the
mastectomy specimen. There was no evidence of
malignancy.
Discussion
Currently available management strategies for women
who carry inherited predisposition to develop breast can-
cer are limited given the lack of prevention methods with
proven efficacy. Furthermore, there have been no prospec-
tive, controlled trials of the breast cancer risk reduction
associated with bilateral prophylactic mastectomy. Such
studies are unlikely to take place due to ethical and prac-
tical considerations. Prophylactic mastectomy, whether
subcutaneous or total, significantly reduces, but does not
eliminate, the risk of breast cancer in high-risk
individuals.
Several studies showed that breast reduction procedures
substantially lower the risk of breast cancer. Recently,
Brinton et al [7] confirmed that the magnitude of cancer
risk reduction is directly related to the amount of tissue
removed during the operation. With a SCM, the nipple-
areola complex is preserved and some of the underlying
breast tissue remains on the skin flaps. When SCM is
intended as prophylaxis against breast cancer, the sur-
geon's aim is to remove as much tissue as possible. It is
plausible that a less thorough removal of glandular tissue
may have taken place given the indication for surgery in
our patient's case. It is generally agreed that the prophylac-
tic nature of bilateral mastectomy in an unaffected BRCA1
or BRCA2 mutation carrier calls for the most complete
breast tissue removal. This viewpoint makes SCM a less
desirable choice. Skin-sparing mastectomy [8] could be
seen as a partial compromise and appears to be an increas-
ingly popular option for women at high risk. More
recently, geneticists have questioned the rejection of sim-
ple SCM as a viable procedure in such women. It is argued
that the magnitude of the risk reduction offered by SCM,
when combined with its greater cosmetic acceptability, is
sufficient to keep this option available to women [9].
There are numerous reports in the literature describing the
occurrence of breast cancer after SCM [10,11].
Subsequently, the perception exists that SCM fails to elim-
inate the risk of breast cancer. Although the extent of risk
reduction achieved by SCM is limited given that about 5–
10% of the mammary tissue remains in situ, it is thought
to be of the order of >85% [4,12]. As stated above [9], at
this level of risk reduction, SCM would have a greater
effect on breast cancer rates in BRCA1/2  carriers than
would total mastectomy if at least 50% of BRCA1/2 carri-
ers chose preventive SCM. Currently, preventive bilateral
total mastectomy rates are about 20% in most
populations.
The first retrospective study of efficacy of prophylactic
mastectomy carried out by Hartmann et al [12] included
18 subjects later confirmed to be carriers of deleterious
mutations in the BRCA genes but, unfortunately, it had
insufficient statistical power to detect a difference in the
risk reduction between total and SCM. In this cohort, all
breast cancers (n = 7) were diagnosed in women who had
undergone SCM (total of 950). None were known to be
BRCA1/2 mutation carriers. Of the seven cases, only one
occurred in the nipple-areolar area. Not surprisingly, the
majority of the high-risk women (n = 17) described in the
subsequent report [3] underwent SCM. After a median of
13.4 years of follow-up, none of the BRCA1/2 germ-line
mutation carriers has developed breast cancer. The
authors concluded that at least 90% risk reduction could
be expected among women with confirmed BRCA muta-
tion status following prophylactic bilateral SCM. Meijers-
Heijboer et al [4] report the initial results of a prospective
study of 76 women with deleterious BRCA1 or BRCA2
mutations who chose to undergo bilateral simple mastec-
tomy and no breast cancers were observed after a mean
follow-up of 2.9 ± 1.4 years. The Prevention and Observa-
tion of Surgical End Points (PROSE) Study Group findings
[5] support the notion that bilateral mastectomy results in
approximately 90% breast cancer risk reduction. Of 105
BRCA mutation carriers, only two women (1.9%) devel-
oped breast cancer 2.3 and 9.2 years after SCM. The first
breast cancer case was diagnosed at the age of 28 years in
the BRCA2 mutation carrier who presented with a palpa-
ble axillary mass at 27 months post-SCM. Subsequently,
metastatic adenocarcinoma in an axillary lymph node was
identified and it was most likely consistent with a primary
breast cancer already present at the time of SCM. It is
important that this case is not considered as a failure of
SCM, and it should be therefore classified as a recurrence
which would have likely taken place despite the surgery.
The second breast cancer case occurred in a BRCA1 carrier
at the age of 41 years.World Journal of Surgical Oncology 2005, 3:52 http://www.wjso.com/content/3/1/52
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When hereditary predisposition to breast cancer is being
assessed, it is important to consider the impact of the age-
related penetrance of the BRCA1  and  BRCA2  genes.
BRCA1 has a higher penetrance than BRCA2 in the pre-
menopausal years [1]. The benefits of preventive surgery
will be proportionally greater for an older BRCA2 carrier
than an older BRCA1 carrier, and therefore if a BRCA2 car-
rier discovers her mutation status when she is peri- or
post-menopausal, the potential benefits of preventive
mastectomy should not be understated, as the breast
cancer risks do not significantly diminish following
menopause.
In our review of the literature (see Table 1), only one pri-
mary breast cancer has been reported to occur in a cohort
of 207 BRCA1/2 mutation carriers who opted for preven-
tive surgery. It could be argued that the efficacy of the
bilateral total mastectomy has not been studied ade-
quately in the high-risk individuals to prove its absolute
superiority over SCM. The total number of the BRCA1 and
BRCA2 carriers who have undergone this type of mastec-
tomy is relatively small and the mean follow-up is rather
short. Furthermore, the presence of a microscopic primary
lesion at the time of surgery may result in subsequent
recurrence that would be impossible to differentiate from
a new primary breast cancer. Based on the above data, the
risk-reducing effect of SCM should not be ignored when
presenting prophylactic mastectomy options to women at
high risk who find total mastectomy unacceptable and
would not otherwise have considered surgical prevention.
Nevertheless, the lack of popularity of this procedure
among surgeons will likely limit its use.
The existing literature on the mammographic and sono-
graphic appearance of breast cancer in BRCA-positive
patients' reconstructed breasts is rather scanty. Pathologic
studies have demonstrated that tumors in BRCA1  and
BRCA2 mutation carriers are associated with morphologic
features of continuous pushing margins [13], with a
reduced potential for stromal infiltration explaining that
this appearence might mimic benign-looking lesions at
mammography [14] and breast sonography as well.
Indeed, sonographic criteria of the mass in our case –
ovoid axis, thin pseudocapsule, posterior enhancement,
and well defined margins – were in keeping with a benign
nodule [15]. In addition, according to Giovagnorio crite-
ria [16], the lesion described in our case, with a single vas-
cular pole (type 2), was compatible with a benign lesion.
Cconsistent with the Lamb et al study [17], this lesion
appeared benign but was in fact a moderate to high-grade
invasive cancer.
Conclusion
We report an unusual case of late occurrence of breast can-
cer after SCM in a BRCA2 mutation carrier. As these cases
are so rare, the long-term risk of breast cancer following
preventive mastectomy in BRCA1/2-positive individuals is
likely to be very low. Nevertheless, vigilant, long-term sur-
veillance based on clinical examination combined with
breast sonography when indicated remains necessary, as
delayed malignancy can occur.
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Table 1: Studies assessing efficacy of bilateral prophylactic mastectomy (PM) in BRCA1 and BRCA2 carriers
Hartmann et al [3] Meijers-Heijboer et al [4] Rebbeck et al [5]
Study recruitment centers USA Netherlands USA, Canada, UK, Netherlands
Median follow-up (yrs) 13.4 2.8 5.5
Mean age at surgery (yrs) 39 36 38
Number of PM patients 18 76 105
Number of controls - 63 378
Type of study Retrospective cohort Prospective cohort Case-control
Primary invasive breast cancer
- in cases (after PM) 0 0 1 (BRCA1carrier)
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